Equities

PhoenixBio Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6190:TYO

PhoenixBio Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)496.00
  • Today's Change-1.00 / -0.20%
  • Shares traded67.20k
  • 1 Year change-2.94%
  • Beta0.5859
Data delayed at least 15 minutes, as of Feb 20 2026 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PhoenixBio Co., Ltd. is a Japan-based company mainly engaged in provision of contract research services of drug development, which uses PXB mouse. The PXB Mouse segment is engaged in the development of technology to create PXB Mouse in which more than 70% of mouse livers are replaced with human hepatocytes. The product called PXB Mouse is used in the preclinical process of the discovery of drugs.

  • Revenue in JPY (TTM)1.60bn
  • Net income in JPY-204.96m
  • Incorporated2002
  • Employees69.00
  • Location
    PhoenixBio Co Ltd3-4-1, KagamiyamaHIGASHIHIROSHIMA-SHI 739-0046JapanJPN
  • Phone+81 824310016
  • Fax+81 824310017
  • Websitehttps://phoenixbio.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
PhoenixBio Co Ltd1.60bn-204.96m2.02bn69.00--1.33--1.26-52.37-52.37396.00372.680.67970.84118.0723,170,680.00-8.71-4.25-10.53-5.5778.4467.17-12.82-7.193.40--0.1831---10.143.29-1,801.92--1.08--
Kringle Pharma Inc72.62m-905.42m2.82bn17.00--2.25--38.86-130.95-130.9510.48170.570.032--1.014,272,000.00-39.93-23.52-42.03-24.93-----1,246.73-349.8916.65-3,738.200.00---9.77-31.17-21.13------
Veritas In Silico Inc91.14m-425.67m3.09bn19.00--1.73--33.95-65.62-65.6214.05274.990.0441--6.11---20.59---21.32-------467.05--18.35-------53.18---80.03------
NPT Co Ltd0.00-266.47m3.41bn7.00--43.82-----54.98-54.980.0015.980.00----0.00-318.44---439.04-------------2,152.880.00-------68.67------
FunPep Co Ltd314.00k-1.91bn3.77bn15.00--2.58--12,014.12-51.03-51.030.008336.090.0001-------75.09-37.74-92.91-41.17-----608,766.90-4,142.723.71-------94.88-36.20-115.00------
Human Metabolome Technologies Inc1.43bn207.06m4.24bn62.0020.242.2313.302.9735.4235.42248.83321.250.623710.294.9123,060,290.009.0310.5410.9813.5960.4866.6514.4817.245.13391.350.055520.988.125.405.42--33.68--
Ribomic Inc750.00k-1.04bn4.56bn25.00--1.42--6,085.26-22.23-22.230.015959.350.0002--0.017330,000.00-31.47-29.95-32.94-31.15-----138,954.00-2,725.9520.66--0.00-----55.550.5173---6.86--
Modalis Therapeutics Corp0.00-2.15bn4.99bn14.00--1.77-----28.13-28.130.0032.230.00-------64.69-47.62-67.23-49.48-------22,365.60-------------63.34---68.51--
D.Western Therapeutics Institute Inc387.62m-632.09m5.43bn21.00--3.78--14.00-13.31-13.318.0926.460.20190.41153.53---32.93-28.15-36.09-30.6889.9792.09-163.07-155.999.48--0.2966---17.801.7451.01---11.74--
Data as of Feb 20 2026. Currency figures normalised to PhoenixBio Co Ltd's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.